UMass Consortium awarded $300,000 from Juvenile Diabetes Research Foundation and Iacocca Foundation

November 01, 2007

WORCESTER, Mass.--Investigators from the University of Massachusetts Medical School (UMMS) will investigate the causes of type 1 diabetes with dual grants from the Juvenile Diabetes Research Foundation (JDRF) and The Iacocca Foundation. The grants, of $150,000 each, will support the research efforts of the UMMS Heat Shock Protein Consortium. Directed by Aldo A. Rossini, MD, the William and Doris Krupp Professor of Medicine and professor of medicine and molecular medicine, the Heat Shock Protein Consortium brings together a unique group of scientists with diverse expertise in the basic sciences.

"The innovation and synergy of the Consortium has already provided a mechanism for interaction and productivity in the field of science," explained Dr. Rossini. "This synergy, we believe, will permit a new area of discovery by bringing together viewpoints of basic cell biology that are now focusing on the understanding of the pathogenesis of type 1 diabetes."

Heat shock proteins (Hsp) are essential proteins that protect the cell from a wide variety of environmental stresses. However, recent studies have demonstrated that altered Hsp function is associated with the development of a number of diseases, including type 1 diabetes. This funding will provide support for a number of innovative studies across a variety of departments and disciplines that aim to understand the Hsp abnormalities that may lead to the development and progression of type 1 diabetes.

"We are committed to supporting young investigators in their development into diabetes-related careers and this important funding will foster creative approaches to the question of the role of cellular stress and autoimmune diabetes," explained Consortium investigator Dale L. Greiner, PhD, professor of medicine.

"Better understanding the pathogenesis of diabetes will help accelerate the pace of science leading to cures and treatments for type 1 diabetes and its complications across a range of research areas," said Richard A. Insel, MD, Executive Vice President for Research at JDRF. "We're thrilled to be partnering with The Iacocca Foundation to fund this important science at the University of Massachusetts Medical School."

Specific laboratories and their respective projects supported by the grants include: "We're excited about this partnership," said Iaccoca Foundation Executive Director Dana Ball. "Our mission is to explore every possible avenue to find a cure for type 1 diabetes and we see incredible promise in the innovative approach UMass is taking."
-end-
About the Juvenile Diabetes Research Foundation

JDRF was founded in 1970 by the parents of children with type 1 diabetes--a disease that strikes children, adolescents, and adults suddenly, makes them insulin-dependent for life, and carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.16 billion to diabetes research worldwide, including $137 million over the past year. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research.

About The Iacocca Foundation

The Iacocca Foundation was established in 1984 to fulfill a promise made by Lee Iacocca to his late wife, Mary Iacocca, who died from complications of type 1 diabetes. Since its inception, the Foundation has funded more than $23 million in promising, breakthrough research projects. The Iacocca Foundation has grown to become a leader in the world's battle against diabetes.

About the University of Massachusetts Medical School

The University of Massachusetts Medical School, one of the fastest growing academic health centers in the country, has built a reputation as a world-class research institution, consistently producing noteworthy advances in clinical and basic research. The Medical School attracts more than $176 million in research funding annually, 80 percent of which comes from federal funding sources. The work of UMMS researcher Craig Mello, PhD, an investigator of the prestigious Howard Hughes Medical Institute (HHMI), and his colleague Andrew Fire, PhD, then of the Carnegie Institution of Washington, toward the discovery of RNA interference was awarded the 2006 Nobel Prize in Physiology or Medicine, hailed as the "Breakthrough of the Year" in 2002 by Science magazine and has spawned a new and promising field of research, the global impact of which may prove astounding. UMMS is the academic partner of UMass Memorial Health Care, the largest health care provider in Central Massachusetts. For more information, visit www.umassmed.edu.

University of Massachusetts Medical School

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.